Table 1 Baseline, disease, transplantation and GVHD characteristics of patients with SR aGVHD in two groups

No. of patients

99

99

Age, median (range), years

28 (16–59)

29 (16–57)

0.680

 < 18 year

14

17

 ≥ 18 year

85

82

Sex

0.385

 Male

62 (62.6%)

56 (56.6%)

 Female

37 (37.4%)

43 (43.4%)

Disease

0.129

 AML

39 (39.4%)

49 (49.5%)

 ALL

45 (45.5%)

43 (43.4%)

 Others*

15 (15.2%)

7 (7.1%)

  MDS

6 (6.1%)

3 (3.0%)

  CML

3 (3.0%)

1 (1.0%)

  MM

1 (1.0%)

0

  NHL

0

1 (1.0%)

  Other acute leukemia

5 (5.1%)

2 (2.0%)

Disease status at transplant

0.524

 CR

63 (63.6%)

70 (70.7%)

 PR

6 (6.1%)

6 (6.1%)

 NR

30 (30.3%)

23 (23.2%)

HLA typing

1.000

 HLA matched

51 (51.5%)

51 (51.5%)

 HLA mismatched

48 (48.5%)

48 (48.5%)

Conditioning

0.200

 Bu-based

51 (51.5%)

42 (42.4%)

 TBI-based

48 (48.5%)

57 (57.6%)

Donor source

0.567

 PBSC

53 (53.5%)

57 (57.6%)

 PBSC + BM

46 (46.5%)

42 (42.4%)

GVHD prevention

0.886

 CsA + MTX or CsA + MTX + MMF

42 (42.4%)

43 (43.4%)

 CsA + MTX + MMF + ATG

57 (57.6%)

56 (56.6%)

Grade of aGVHD

0.771

 Grade 2

36 (36.4%)

37 (37.4%)

 Grade 3

41 (41.4%)

44 (44.4%)

 Grade 4

22 (22.2%)

18 (18.2%)

No. of aGVHD involved organs

0.589

 1

25 (25.3%)

29 (29.3%)

 2

46 (46.5%)

48 (48.5%)

 3

28 (28.3%)

22 (22.2%)

aGVHD involved organs

0.860

 Skin

73 (73.7%)

63 (63.6%)

 Liver

43 (43.4%)

46 (46.5%)

 Upper GI

9 (9.1%)

10 (10.1%)

 Lower GI

79 (79.8%)

77 (77.8%)

Onset of aGVHD median days (range)

30 (14–132)

28 (16–124)

0.736